Please assess the completion status of the following clinical trial:

Trial Title: ChampioNIR® SFA Stent EFS Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years and of age of legal consent.~2. Subject has lifestyle limiting claudication or rest pain (Rutherford-Becker scale 2-4) with a resting ankle-brachial index/toe-brachial index (ABI/TBI) \<0.90/0.80.~3. A single superficial femoral artery lesion with \>50% stenosis or total occlusion.~4. Stenotic lesion(s) or occluded length within the same vessel (one long or multiple serial lesions) ≥ 40 mm to ≤ 140 mm.~5. Reference vessel diameter (RVD) ≥ 3.0 mm and ≤ 6.0 mm by visual assessment.~6. Target lesion located with the distal point at least 3 cm above the knee joint, defined as the distal end of the femur at the knee joint, and proximal point at least 2 cm below the origin of the profunda femoris (deep femoral artery).~7. Patent infra-popliteal and popliteal artery, i.e., single vessel runoff or better with at least one of three vessels patent (\<50% stenosis) to the ankle or foot.~8. The target lesion(s) can be successfully crossed with a guide wire and dilated.~9. The subject is eligible for standard surgical repair, if necessary.~10. Subjects are willing to comply with scheduled visits and tests and are able and willing to provide informed consent.~Exclusion Criteria:~1. Thrombophlebitis or deep venous thrombus, within the previous 30 days.~2. Presence of thrombus in the treated vessel as visualized by angiography, prior to crossing the lesion.~3. Thrombolysis of the target vessel within 72 hours prior to the index procedure, where complete resolution of the thrombus was not achieved.~4. Poor aortoiliac or common femoral inflow (i.e. angiographically defined \>50% stenosis of the iliac or common femoral artery) that would be deemed inadequate to support a femoro-popliteal bypass graft and was not successfully treated prior to treatment of the target lesion.~5. Presence of residual ≥30% stenosis after either PTA or stenting of the inflow lesion.~6. Presence of an ipsilateral arterial artificial graft.~7. Ipsilateral femoral aneurysm or aneurysm in the SFA or popliteal artery.~8. Lesions in contralateral SFA/PPA that require intervention during the index procedure, or within 30 days before or after the index procedure;~9. Required stent placement (in the target or any other lesion) via a retrograde approach.~10. Required stent placement (in the target or any other lesion) across or within 0.5 cm of the SFA / PFA bifurcation.~11. Procedures which are pre-determined to require stent-in-stent placement to obtain patency, such as in-stent restenosis.~12. Significant vessel tortuosity or other parameters prohibiting access to the lesion or 90° tortuosity which would prevent delivery of the stent device.~13. Required stent placement within 1 cm of a previously (in a former procedure) deployed stent.~14. Use of atherectomy or other atheroablative (e.g. cryoplasty) devices at the time of index procedure.~15. Restenotic lesion that had previously been treated by atherectomy, laser or cryoplasty within 3 months of the index procedure.~16. Subject has tissue loss, defined as Rutherford-Becker classification category 5 or 6.~17. Coronary intervention within 7 days prior to or planned within 30 days after the treatment of the target lesion.~18. Stroke within the previous 90 days.~19. Known allergies to any of the following: aspirin, P2Y12 inhibitors (clopidogrel bisulfate, prasugrel, OR ticagrelor), heparin OR bivalirudin, nitinol (nickel titanium), or contrast agent, that cannot be medically managed.~20. Receiving dialysis or immunosuppressant therapy within the previous 30 days.~21. Known or suspected active infection at the time of the procedure.~22. History of neutropenia, coagulopathy, or thrombocytopenia.~23. Known bleeding or hypercoagulability disorder or significant anemia (Hb\<8.0) that cannot be corrected.~24. Platelet count \<80,000/μL~25. International normalized ratio (INR) \> 1.5~26. GFR \<30 ml/min by Cockroft-Gault.~27. Subject requires general anesthesia for the procedure.~28. Subject has a co-morbid illness that may result in a life expectancy of less than 1 year~29. Planned use of a drug coated balloon (DCB) during the index procedure.~30. Pregnant women or women of child bearing potential who do not have a negative serum or urine pregnancy test documented within 7 days prior to enrollment;~31. Subject is participating in any investigational study that has not yet reached its primary endpoint.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single are (Type: EXPERIMENTAL): This study is designed as an early feasibility, prospective, open label, single arm study. 30 patients with infra-inguinal peripheral arterial disease appropriate for treatment with a femoro-popliteal stent will be treated with ChampioNIR® SFA stent implantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).